Nabriva Therapeutics AG ADR | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
Sales/Revenue
-
-
3,746.70
6,463.20
Cost of Goods Sold (COGS) incl. D&A
143.00
125.00
-
-
Gross Income
143.00
125.00
-
-
SG&A Expense
10,050.00
9,816.00
31,203.20
61,118.30
EBIT
10,193.00
9,941.00
-
54,887.50
Unusual Expense
381.00
585.00
-
-
Non Operating Income/Expense
24,905.00
835.00
19,559.20
855.50
Interest Expense
4,017.00
5,817.00
-
-
Pretax Income
10,537.00
14,336.00
47,153.90
55,401.00
Income Tax
673.00
956.00
442.60
670.10
Consolidated Net Income
11,210.00
13,380.00
46,711.30
54,730.90
Net Income
11,210.00
13,380.00
46,711.30
54,730.90
Net Income After Extraordinaries
11,210.00
13,380.00
46,711.30
54,730.90
Net Income Available to Common
11,210.00
13,380.00
46,711.30
54,730.90
EPS (Basic)
0.53
0.63
4.41
2.55
Basic Shares Outstanding
21,161.20
21,161.20
10,584.00
21,478.30
EPS (Diluted)
0.49
0.63
4.78
2.55
Diluted Shares Outstanding
21,161.20
21,161.20
10,584.00
21,478.30
EBITDA
10,050.00
9,816.00
27,456.40
54,655.10
Non-Operating Interest Income
223.00
2.00
13.90
342.00
About Nabriva Therapeutics
View Profile
